Merck’s New Spinoff Organon Shows How Women’s Health Can Provide Fertile Ground For Investment. Here’s Why. Considering the global women’s health market is predicted to be worth $50 billion by 2025, it seems somewhat ironic that one of the more silent voices tends to be that of Big Pharma.